Sugi Predict

Sugi Predict / Compounds / Gedatolisib

Gedatolisib

Gedatolisib

SCHEMBL20765154

CN(C)C1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(-c4nc(N5CCOCC5)nc(N5CCOCC5)n4)cc3)cc2)CC1.CS(=O)(=O)O

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5

The experimentally established mechanism targets of Gedatolisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ MTOR known ✓ P42345 19/20 0.93
▸ PIK3CA known ✓ P42336 18/20 0.93
▸ PIK3CG known ✓ P48736 8/20 0.93
▸ PIK3CB known ✓ P42338 3/20 0.93
▸ PIK3CD known ✓ O00329 2/20 0.93
▸ PIK3R1 known ✓ P27986 1/20 0.73
▸ PIK3C2B O00750 1/20 0.93
▸ PIK3C3 Q8NEB9 1/20 0.93

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gedatolisib SCHEMBL20765097 0.96 MTOR (1.00) MTORPIK3CAPIK3CGPIK3CBPIK3CD
Gedatolisib SCHEMBL32393 0.96 MTOR (1.00) MTORPIK3CAPIK3CGPIK3CBPIK3CD
Gedatolisib SCHEMBL20765101 0.96 MTOR (0.88) MTORPIK3CAPIK3CGPIK3CBPIK3CD
SCHEMBL32727 0.94 MTOR (0.95) MTORPIK3CAPIK3CGPIK3CBPIK3CD
SCHEMBL32828 0.93 MTOR (0.93) MTORPIK3CAPIK3CGPIK3CBPIK3CD
SCHEMBL32433 0.92 MTOR (0.91) MTORPIK3CAPIK3CGPIK3CBPIK3CD
Gedatolisib SCHEMBL29047454 0.91 MTOR (0.90) MTORPIK3CAPIK3CGPIK3CBPIK3CD
SCHEMBL32600 0.91 PIK3CA (0.90) MTORPIK3CAPIK3CGPIK3CBPIK3CD
SCHEMBL32250 0.91 PIK3CA (0.90) MTORPIK3CAPIK3CGPIK3CBPIK3CD
SCHEMBL32634 0.91 PIK3CA (0.90) MTORPIK3CAPIK3CGPIK3CBPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4249069-B1 AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA PFIZER (US) 2025-11-19 — — EP claimed
EP-4249069-A2 AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA Pfizer Inc. (US) 2023-09-27 — — EP claimed
US-11541058-B2 Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea PFIZER INC. (US) 2023-01-03 — — US claimed
EP-3672571-B1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA PFIZER (US) 2021-10-06 — — EP claimed
EP-3672571-A1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA Pfizer Inc. (US) 2020-07-01 — — EP claimed
WO-2019038657-A1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA PFIZER INC. (US) 2019-02-28 — — WO claimed
US-20230218628-A1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA PFIZER LIMITED (GB) 2023-07-13 — — US disclosed
US-11541058-B2 Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea PFIZER INC. (US) 2023-01-03 — — US disclosed
EP-3672571-B1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA PFIZER (US) 2021-10-06 — — EP disclosed
EP-3672571-A1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA Pfizer Inc. (US) 2020-07-01 — — EP disclosed
WO-2019038657-A1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA PFIZER INC. (US) 2019-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218628-A1 PHARMACEUTICAL AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA CYP2D6, OPRM1, ADRM1 MTOR 2524/4885PIK3CA 2618/4885PIK3CG 2094/4885
US-11541058-B2 Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea CYP2D6, OPRM1, ADRM1 MTOR 2524/4885PIK3CA 2618/4885PIK3CG 2094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.